Peptides DB
Research-centric peptide and protocol reference hub

L-Carnitine (Levocarnitine) record · updated 7h ago

Metabolic & appetiteMuscle & body compGrade A · human clinicalResearch use only
All 7 studiesJump to the evidenceCompare
What is L-Carnitine (Levocarnitine) used for?

L-Carnitine (levocarnitine) is an amino acid derivative that shuttles long-chain fatty acids into mitochondria for energy production, studied for metabolic, cardiovascular, and exercise performance applications.

Primarily researched for · Metabolic & appetite

Development stage

where L-Carnitine (Levocarnitine) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Current
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 34 registered trials. It describes the research record, not a recommendation.

Identity
NameL-Carnitine (Levocarnitine)
Full name—
Sequence—
ClassMetabolic
Research levelExtensively Studied
Discovered byCurated master list · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
Metabolic & appetite: Healing 1.0, Muscle 4.0, Metabolic 5.0, Neuro 2.0, Sleep 1.0, Immune 2.0, Skin 3.0Healing & recovery — 1.0 / 5Muscle & body comp — 4.0 / 5Metabolic & appetite — 5.0 / 5Neuro & mood — 2.0 / 5Sleep & circadian — 1.0 / 5Inflammation & immune — 2.0 / 5Skin & aesthetics — 3.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin1.04.05.02.01.02.03.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 3, 2026. How this works →
Research stats
Total studies7
Human / animal / cellular5 / 1 / 0
Highest trial phasePhase 1
Years covered2023–2026
Latest study2d ago
Publication history
20232026
Research funding
376 NIH projects · $24.0M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports70
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

7 rowsOpen in the library →
StudyTypeYearSummary depth
Calcium tartrate tetrahydrate bladder stone.
TakeawayNot reported in abstract.
—2026Title only0.10
Effects of different oxygen concentrations during intermittent hyperoxic training on endurance capacity in well-trained male mice.
Finding0.76-fold lower glutathione peroxidase-1 protein levels in PL muscle in INT75 vs ET.
Animal2026Full text read0.70
Expanded Hemodialysis Using a Medium Cut-Off Dialyzer for Severe Valproic Acid Poisoning: A Case Report with Real-Time Therapeutic Drug Monitoring.
FindingVPA decreased to 97.81 µg/mL at 4 h (62.8% reduction).
Human2023Full text read0.80
Riboflavin treatment in L-2-hydroxyglutaric aciduria: report on a pediatric patient and literature review.
FindingNot reported in abstract.
Human2025Full text read0.80
First-in-human nuclease-free homologous recombination-dependent gene editing in pediatric patients with methylmalonic acidemia: results of a phase 1/2 study.
FindingNot reported in abstract.
Human2026Full text read0.80
Clinical and Genetic Characteristics of Mitochondrial DNA Depletion Syndrome Associated with SUCLG1 Variants in China.
Finding14 SUCLG1 variants identified.
Human2026Full text read0.80
Comparative Analysis of L-Carnitine and Coenzyme Q<sub>10</sub> Adverse Reaction Reports Using the EudraVigilance Database: Implications for Health and Sports Supplementation.
Finding34.2% serious cases for L-carnitine, 74.5% serious cases for CoQ10.
Human2023Full text read0.80

Articles mentioning L-Carnitine (Levocarnitine)